RxDoctor Payments Data

Thomas Barman, MD

Internal Medicine · Salt Lake City, UTNPI 1881704286

Payments from drug & device makers

$408in general payments, 2019–2025

Across 22 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$161
  • Lilly USA, LLC$45
  • Dexcom, Inc.$35
  • Boehringer Ingelheim$29
  • Pfizer$28
  • Xeris Pharmaceuticals, Inc.$24
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$408 in reported general payments places this provider in the 65th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$146,252
Medicare patients
298
Services billed
3,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$161,777
JardianceEmpagliflozin169$160,045
MounjaroTirzepatide102$125,921
TrulicityDulaglutide17$34,560
XareltoRivaroxaban23$25,894
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$24,820
Repatha SyringeEvolocumab11$20,853
JanuviaSitagliptin Phosphate12$20,364
OzempicSemaglutide17$14,980
Lantus SolostarInsulin Glargine,hum.Rec.Anlog100$13,408
Atorvastatin Calcium1,117$10,265
Breo ElliptaFluticasone/Vilanterol15$9,691
Omeprazole470$8,197
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$7,406
Synjardy XrEmpagliflozin/Metformin Hcl15$6,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$29$166,187184 claims
PfizerEliquis$28$161,777186 claims
Lilly USA, LLCMounjaro, Trulicity$45$160,481119 claims
Johnson & JohnsonXarelto$18$25,89423 claims
Novo NordiskOzempic$19$14,98017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →